1. Universidade Federal do Rio Grande do Norte
2. Centro de Biociências
3. DBF - Departamento de Biofísica e Farmacologia
4. CB - DBF - Artigos publicados em periódicos

Title:	Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia
Other Titles:	A via receptor NMDA-óxido nítrico-GMP cíclico como alvo para o desenvolvimento de medicações antipsicóticas não-dopaminérgicas para a esquizofrenia
Authors:	Soares, Bruno Lobão Oliveira, João Paulo Maia de Machado-de-Sousa, João Paulo Baker, Glen B. Dursun, Serdar Hallak, Jaime E. C.
Keywords:	Schizophrenia
Issue Date:	Sep-2011
Publisher:	Associação Brasileira de Psiquiatria
Citation:	SOARES, Bruno Lobão et al.Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia. Revista Brasileira de Psiquiatria, v. 33, p. 223-224, 2011. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462011000300003&lng=en&tlng=en>. Acesso em: 23 mar. 2018.
Portuguese Abstract:	Schizophrenia is a devastating disorder that occurs in about 1% of the population worldwide. For over 30 years, it has been considered to be the result of dysfunctional brain dopaminergic pathways. However, dopaminergic antipsychotic drugs have proven effective for only some of the symptoms found in schizophrenia patients. Recent evidence suggests that dopaminergic abnormalities may be secondary to dysfunctions in multi-neurotransmitter systems modulating dopamine. One of the key neurotransmitters thought to be involved in schizophrenia is glutamate, and there is strong support for the involvement of a hypoactivity of N-methyl-D-aspartate (NMDA) glutamate receptors in the pathogenesis of schizophrenia. However, research with NMDA receptor agonists for the treatment of schizophrenia has produced inconsistent results, which may be due to the development of rapid tolerance to these compounds secondary to down-regulation of NMDA receptors. Perhaps the development of drugs that act on targets downstream NMDA receptors, such as nitric oxide (NO), could avoid the problem of the down-regulation of these receptors.
URI:	https://repositorio.ufrn.br/jspui/handle/123456789/25437
ISSN:	1809-452X
Appears in Collections:	CB - DBF - Artigos publicados em periódicos

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.